摘要
目的观察高剂量艾迪注射液联合环磷酰胺(CTX)、氨甲喋呤(MTX)、5-氟尿嘧啶(5-Fu)3种化疗药物(CMF方案)治疗Ⅱ、Ⅲ期乳腺癌患者的疗效.方法随机将100例患者分成采用高剂量艾迪注射液联合CMF方案的治疗组60例和单用CMF方案治疗的对照组40例.结果治疗组临床症状及肿瘤面积均有较明显的改善和缩小,治疗效果明显优于对照组.两组主要毒副反应为恶心、呕吐和外周白细胞总数减少,以1～2度多见,未见4度毒性反应.但治疗组白细胞减少3度以上者较对照组少,两组比较有显著差异性(P＜0.05).两组1～3年生存率无显著差异(P＞0.05),但5年生存率差异显著(P＜0.05).结论艾迪注射液具有清热解毒、消淤散结功能,不但对肿瘤细胞有较强的抑制杀灭作用,而且能显著提高患者的免疫功能,延长生存期,降低化疗引起的外周白细胞减少的程度.艾迪注射液为一种高效低毒的抗癌新药,值的临床推广使用.
Objective To explore the curative effects of the combined use of cytoxan （CTX）. Methotrexate （MTX） and 5-fluorouracil （5-FU） and aidi injection in treating mammary cancer at Stage Ⅱ and Stage Ⅲ. Methods 100 cases were randomly divided into the treatment group of combined therapy （60 cases） and the contrast group of simple use of chemotherapy （40 Cases）. Results Clinical symptoms got improved and the tumor area shrank more greatly in the treatment group than in the contrast group. Nausea, vomiting and decrease in peripheral white cells occurred in both groups. Toxic response of Grade Ⅰ and Grade Ⅱ happened frequently, while no Grade Ⅳ toxic response occurred in both groups. Grade Ⅲ toxic response occurred less in thtreatment group than in the contrast group. No difference in the first 1-3 years of survival in the two groups were found （ P 〉 0.05）, but significant difference in the survival rates of 5 years （ P 〈 0.05）. Conclusion Aidi injection can effectively trnprove immunologic functions, prolong patients＇ survival expectancy and produce good curative effects on mammary cancer.
出处
《临沂医学专科学校学报》
2005年第5期341-343,共3页
Journal of Linyi Medical College
